One of the key learning outcomes of university education in general, and liberal arts programmes,  in particular, is that ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

Digital asset regulation finally shifted into gear in 2025 as the US moved toward a more crypto-friendly legal framework and ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of ...

In comparison, he writes, the 300,000 years since Homo sapiens evolved is so brief that “in a single stroke with a medium-grained nail file you could eradicate human history.” In this special issue on ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...